Category: Press Release

Social Media

Geistlich Expands its Partnership with Meisinger and Launches the Master-Pin-Control System

FOR IMMEDIATE RELEASE
February 4, 2026

Geistlich Expands its Partnership with Meisinger – Launches the Master Pin Control Kit, Pin System

PRINCETON, NJ — Geistlich Pharma North America is proud to announce the expansion of its collaboration with Meisinger through the launch of the Master-Pin-Control Kit, a precision fixation system designed to further enhance outcomes in regenerative dental procedures.

Developed by Dr. Istvan Urban, the Master-Pin-Control system is specifically engineered for the fixation of resorbable, non-resorbable, and titanium membranes. Crafted from Grade 5 titanium alloy, each pin features a small groove design that allows it to be inserted like a pin and easily removed like a screw.

The sharp tip and robust structure enable precise placement into cortical bone, and the innovative threading ensures easy, safe removal after successful healing. This innovative design allows clinicians to achieve more secure membrane fixation and reduces the risk of complications.

“Our partnership with Meisinger continues to deliver meaningful innovation to our customers,” said Les Burrows, General Manager of Geistlich Pharma North America. “The opportunity to add the Master-Pin-Control system to our growing biomaterials product portfolio is exciting and enhances our fixation system products for our customers.”

“Our partnership with Meisinger continues to deliver meaningful innovation to our customers.”

— Les Burrows, General Manager, Geistlich Pharma North America

About Meisinger

As one of the oldest and most efficient manufacturers of dental rotary instruments, MEISINGER has always been a pioneer in the field of precision work. With a consistent focus on the needs of dental practices and dental laboratories, Meisinger has assumed a leading position in the dental industry.

About Geistlich North America Inc.

Geistlich’s legacy of scientific collaboration, product excellence, and clinical outcomes is what makes Geistlich Biomaterials Exactly Like No Other.

Media Contact:
Jamie Bratton
[email protected]

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

Takeover and transformation: Geistlich lays the foundation for innovation

In 1899, Eduard Geistlich recognizes a unique opportunity: he takes over the bankrupt hosiery and button factory in Wolhusen and transforms it into a modern glue and fertilizer factory within a very short time. At just 18 years of age, Eduard Geistlich Jr. ushered the factory into a new era – bone and skin glues, fats, and organic fertilizer became the main products.

But his pioneering spirit extended far beyond the factory: after the completion of the Simplon Tunnel, Geistlich employed skilled workers who had become available to blast a water channel into the rock. The water obtained from this powered the company’s own hydroelectric power plant, which supplied electricity not only to the factory but also to three villages. The electrification of the region began as early as 1908 – a milestone for progress and sustainability.

With the founding of the family-owned public limited company Ed. Geistlich Söhne AG in 1909, the company embarks on the path to a modern corporate structure – and remains true to its tradition and innovative strength to this day.

How it all began – with pioneering spirit and responsibility

Eduard Geistlich was a central figure in the history of the company. He was not only an entrepreneur, but also very committed to the region.

Eduard Geistlich, then 16 years old, joined the company in 1872 and took it over as sole owner in 1884. With visionary entrepreneurial spirit, he expanded Geistlich into an internationally successful business. Despite high protective tariffs and strong competition, the products impressed with their quality and made the Geistlich brand known throughout Europe.

But Eduard Geistlich was more than just an entrepreneur: he brought electricity to Schlieren for the first time, participated in the construction of the Limmattalbahn railway, and installed the first telephone in the area. His commitment to the community set new standards—from the kindergarten and welfare center to the promotion of housing for employees.

This pioneering spirit lives on today: Geistlich stands for innovation, responsibility, and social commitment—then as now.

From glue hut to industry icon:
the beginnings of the Geistlich company

175 years ago, a success story began in Zurich with a craft as old as humanity itself: by founding Switzerland’s first glue factory, Heinrich Glättli and Heinrich Geistlich laid the foundation for the Geistlich company—a pioneering enterprise that continues to combine tradition and innovation to this day.

The history of the Geistlich company begins in 1825 with the birth of Heinrich Geistlich in Greifensee. As a master locksmith in Meilen, he worked for his fellow believer Heinrich Glättli, who founded Switzerland’s first glue factory in Riesbach in 1851 – the so-called “Lymhütte.” This factory marks the origin of today’s Geistlich company. Even today, the “Leimgasse” (Glue Alley) in the Zurich district commemorates this historic location.

The history of glue dates back to the Stone Age. Advanced civilizations such as the Egyptians, Greeks, and Romans used animal substances for gluing. In the Middle Ages, glue was mainly in demand for bookbinding and woodworking. With the Enlightenment, knowledge of the chemical principles behind glue increased. From the 20th century onwards, technological advances led to synthetic adhesives that are more durable and versatile.

Geistlich shaped glue production for over 150 years – by combining traditional craftsmanship and modern technology, a simple product became an innovative industry.

Geistlich Enters a Manufacturing and Supply Partnership with Meisinger

FOR IMMEDIATE RELEASE
December 10, 2025

Geistlich Enters a Manufacturing and Supply Partnership with Meisinger

PRINCETON, NJ — Geistlich Pharma North America is pleased to announce the launch of the Meisinger Screws and the Meisinger Screw System TX. Meisinger is a globally recognized leader in dental surgical instruments. Founded in 1888, Meisinger has over 135 years of precision German manufacturing. They are known for combining innovation with reliability and offer fixation solutions that are trusted by clinicians worldwide.

The Meisinger Screw System TX is an all-purpose screw system for simple and safe fixation of bone segments. The unique Torx connection guarantees reliable accommodation of the screws in the screwdriver and allows for the transfer of high tensile forces. A large diameter rescue screw is also included should high tensile fixation is not possible.

The Meisinger Screws enable the universal use of fixation for autogenous bone cylinders, bone blocks, and bone shells for pre-implant augmentation procedures, and can also be used to securely fixate Yxoss CBR® meshes for precise scaffold stabilization. The screw thread goes up to the head of the screws which allows for the sandwich or bone shell augmentation. The small diameter and the low head size of the screws allow for a comfortable application for patient and user.

“We are excited to partner with Meisinger, a company that shares our commitment to precision, clinical excellence, and education,” said Les Burrows, General Manager, Geistlich Pharma North America. “This partnership strengthens our portfolio, especially with our product Yxoss CBR® by combining Geistlich’s regenerative expertise with the confidence and reliability of the Meisinger Screws and Screw System TX, supporting clinicians in even the most complex bone regeneration cases.”

“We are excited to partner with Meisinger, a company that shares our commitment to precision, clinical excellence, and education.”

— Les Burrows, General Manager, Geistlich Pharma North America

About Geistlich North America Inc.

Geistlich’s legacy of scientific collaboration, product excellence, and clinical outcomes is what makes Geistlich Biomaterials Exactly Like No Other.

Media Contact:
Jamie Bratton
[email protected]

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

More information about Geistlich Bio-Gide® Forte

Geistlich Bio-Gide® Forte: Trusted Technology with Advanced Handling

FOR IMMEDIATE RELEASE

PRINCETON, NJ — Geistlich is presenting Geistlich Bio-Gide® Forte, a new membrane based on proven collagen technology. It offers greater strength, is easy to handle, and adapts to the ridge contour. The resorbable membrane will be unveiled at the annual meeting of the American Academy of Periodontology (AAP).

Geistlich continuously expands its product portfolio to provide clinicians and patients worldwide with even more regenerative solutions. The family-owned company is launching Geistlich Bio-Gide® Forte, an advanced collagen membrane that supports reliable bone regeneration and optimal tissue integration. With its differentiated handling properties and high tensile strength, Geistlich Bio-Gide® Forte is designed for use in a wide range of bone and soft tissue regeneration cases.^1,2

Proven Geistlich Bio-Gide® technology with added strength
Mark Spilker, Chief Science Officer at Geistlich, says: “With Geistlich Bio-Gide® Forte, we are expanding our membrane portfolio by offering a version of Geistlich Bio-Gide® that delivers particularly robust handling.” Geistlich Bio-Gide® Forte is particularly firm and stable when hydrated. The membrane unfolds easily, can be cut even when hydrated, and enables tailoring to defect size and shape, providing precise adaptation and optimal coverage .¹ Building on the excellent properties of Geistlich Bio-Gide® technology, the new product also helps to improve the survival rate of implants.³

“With Geistlich Bio-Gide® Forte, we are expanding our membrane portfolio by offering a version of Geistlich Bio-Gide® that delivers particularly robust handling.”

— Mark Spilker, Chief Science Officer, Geistlich Pharma AG

About Geistlich North America Inc.

Geistlich’s legacy of scientific collaboration, product excellence, and clinical outcomes is what makes Geistlich Biomaterials Exactly Like No Other.

Media Contact:
Jamie Bratton
[email protected]

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

Data on File, Usability Test 2025, Geistlich Pharma AG, Wolhusen, Switzerland.
Dewilde F, Hindryckx M, Younes F, Bruyckere TD, Cosyn J. Clin. Implant Dent. Relat. Res. 2024.doi:10.1111/cid.13313 Epub ahead of print.
Knofler W, Barth T, Graul R, Krampe D. International journal of implant dentistry 2016.;2:25.

Recapping the Incredible 2025 ISPRD Event in Boston

What an unforgettable week at ISPRD! We were thrilled to connect with so many leading dental professionals and share our latest innovations in regenerative dentistry. The energy, visibility, and engagement at the meeting were incredible, and we hope this recap gives you a sense of the momentum and experience we created as a team there!

The Geistlich Corporate Forum was a resounding success, featuring a stellar lineup of experts who shared invaluable insights into the future of dental regeneration. The Corporate Forum included an all-star lineup of clinicians from around the world! Doctors Kurmar, Schallhorn, Rocchietta, and Urban delivered outstanding lectures on the Geistlich full portfolio.

Following the corporate forum, the Geistlich All-Access Lounge debuted across from the booth and was packed all weekend. For a more informal and interactive experience, our All-Access Lounge was the ideal spot. With a “Rockstar-Level Experience” theme, attendees had the opportunity for hands-on demonstrations of our new products and scored some exclusive Geistlich swag. Clinicians stopped by for Yxoss® and Micross Curve product demos, exclusive swag, and daily “Regenerate Yourself” snack breaks. Our custom scrub cap printing was a showstopper—people lined up daily, and we completely sold out in just 1.5 days!

Of course, we can’t forget to mention our hugely successful networking event with our partners from the Osteology Foundation. This event drew over 100 doctors from around the United States. Hosted in the hotel’s main lobby restaurant with a live DJ, our networking event was the place to be in Boston for both younger and veteran clinicians.

We extend a sincere “thank you” to the organizers of ISPRD for putting on an exceptional symposium. And to everyone who stopped by our booth, attended our events, and shared your passion with us – you made this a truly memorable week. We are already looking forward to the next opportunity to connect and continue to shape the future of regenerative dentistry together!

The Geistlich Corporate Forum was a resounding success, featuring a stellar lineup of experts who shared invaluable insights into the future of dental regeneration.

About Geistlich North America Inc.

With more than 170 years of regenerative expertise, Geistlich continues to set the global standard in oral regeneration. The company offers a comprehensive portfolio of clinically proven biomaterials, including the world-renowned Geistlich Bio-Oss®, Geistlich vallomix™, and a full line of allografts under the vallos® brand.

Geistlich’s legacy of scientific collaboration, product excellence, and clinical outcomes is what makes Geistlich Biomaterials Exactly Like No Other.

Media Contact:
Jamie Bratton [email protected]

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

Geistlich Expands Innovative Product Portfolio with Launch of Micross Curve

FOR IMMEDIATE RELEASE
June 12, 2025

Geistlich Expands Innovative Product Portfolio with Launch of Micross Curve

PRINCETON, NJ — Geistlich Pharma North America is proud to announce the launch of the Micross Curve, the latest innovation with META and the newest addition to the trusted META Family of regenerative tools.

Geistlich wants to expand the treatment spectrum of its regenerative products through in-house developments, acquisitions and partnerships and make it accessible to an even larger group of patients. One example of this is the medical technology company Meta Technologies s.r.l., which has been part of Geistlich since 2021. Its instruments are considered the gold standard in dentistry.

Engineered for enhanced precision and ease of use, the Micross Curve is designed to advance the field of minimally invasive bone harvesting. Building on the proven success of the original Micross, the Micross Curve incorporates a bent, micro-sized blade based on Safescraper® Twist technology—making it one-third smaller than the original Safescraper blade while retaining its key benefits.

Featuring a slim, ergonomic design, the Micross Curve is ideal for use in narrow or hard-to-reach anatomical sites. Its curved tip ensures optimal visibility and comfort during clinical procedures, enabling clinicians to access challenging areas with improved control and handling.

“We are excited to bring the Micross Curve to market as we continue our commitment to providing advanced regenerative solutions,” said Les Burrows, General Manager, Geistlich Pharma North America. “This addition represents another step forward in supporting clinicians with tools designed for precision, safety, and efficiency.”

To learn more about the Micross Curve or explore Geistlich’s full range of regenerative solutions, visit: https://geistlich.us

Geistlich Pharma North America announced today the launch of its latest innovation with META: the Micross Curve, the newest addition to the Micross family!

About Geistlich North America Inc.

Geistlich’s legacy of scientific collaboration, product excellence, and clinical outcomes is what makes Geistlich Biomaterials Exactly Like No Other.

Media Contact:
Jamie Bratton [email protected]

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

References

Righesso, L A R et al. “Dynamic contrast-enhanced magnetic resonance imaging for monitoring neovascularization during bone regeneration-a randomized in vivo study in rabbits.” Clinical oral investigations vol. 25,10 (2021): 5843-5854. doi:10.1007/s00784-021-03889-6
Zaffe, Davide, and Ferdinando D’Avenia. “A novel bone scraper for intraoral harvesting: a device for filling small bone defects.” Clinical oral implants research vol. 18,4 (2007): 525-33. doi:10.1111/j.1600-0501.2007.01368

Learning from the best with Geistlich myGuide®

Geistlich is proud to announce the launch of Geistlich myGuide®, the world’s first complete online learning journey in regenerative dentistry. This enables clinical professionals to learn from leading experts in the field of dental regeneration and to continuously educate themselves regardless of time and place.

Sharing expertise in the field of medical regeneration is deeply rooted in Geistlich’s DNA. From experience, the Swiss manufacturer of Geistlich Bio-Oss^® and Geistlich Bio-Gide^® knows that about 80 percent of the questions related to implant treatments concern regeneration.

Previous training courses in this area have mostly included individual lectures, hands-on workshops, or webinars. However, structured online learning offers have hardly existed to date. Geistlich wants to close this gap with Geistlich myGuide^®.

A pioneering offer for regenerative dentistry

With Geistlich myGuide^®, clinical professionals from around the world will have the opportunity to learn from the best clinicians and scientists in the field of dental regeneration. A total of 27 internationally renowned experts have created the content. The scientific partner for Geistlich myGuide^® is Prof. Dr. Ronald E. Jung from the University of Zurich. Under his guidance, the structure, scope, and learning objectives of this learning journey have been created.

“Geistlich myGuide^® is a highly innovative development that takes regenerative dentistry education to the next level. Geistlich myGuide^® puts patients first and offers regenerative solutions for all indications.” Prof. Dr. Ronald E. Jung, Director Clinic of Reconstructive Dentistry, University of Zurich

All course content builds on each other, ensuring a structured learning process. At the same time, Geistlich myGuide^® is very much geared to everyday clinical practice. Pure theory modules have been deliberately avoided.

Wide range of practice-oriented learning content

Five different learning formats are used: so-called e-learning modules that are 100 percent responsive. This means that learning is possible without restrictions on all mobile devices. In addition, uncut clinical videos, clinical case documentation, hands-on courses in the form of online workshops conducted from home, and, of course, assessment modules for a knowledge check are integrated.

Dr. Andreas Geistlich, Chairman of the Board of Directors at Geistlich, says: “Supporting the dental community and ensuring the best possible care for patients is part of Geistlich’s DNA. With the introduction of this innovative educational journey, we are opening new perspectives for continuing education in dentistry. I am impressed!”

Clinical professionals from around the world are invited to join this educational journey and actively shape the future of regenerative dentistry.

Learn more about this new offering in regenerative dentistry and start your learning journey today at www.geistlich-myguide.com. This educational offering is initially available in English. However, other language versions are planned in the medium term.

Geistlich is proud to announce the launch of Geistlich myGuide®, the world’s first complete online learning journey in regenerative dentistry. This enables clinical professionals to learn from leading experts in the field of dental regeneration and to continuously educate themselves regardless of time and place.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

This begins with our world-class bone substitute Geistlich Bio-Oss^® and Geistlich vallomix™, the first allograft/xenograft bone substitute. Resorbable collagen membrane Geistlich Bio-Gide^® extends its reach with Geistlich Bio-Gide^® Compressed for an alternative handling experience.

Our collagen matrix Geistlich Mucograft^® is ideal for soft-tissue regeneration, and our volume-stable collagen matrix breakthrough Geistlich Fibro-Gide^® provides an alternative to connective tissue grafts. Finally, our GEM 21S®, a growth-factor-enhanced matrix, is engineered to stimulate wound healing and bone regeneration.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

Geistlich Announces Exciting Product Line Extension from Reoss: Yxoss CBR® Fully Protect

April 9, 2024

Geistlich Pharma North America announced today the launch of Reoss’s latest innovation, Yxoss CBR® Fully Protect, the newest addition to the Yxoss CBR® Family!

Now there are three Yxoss CBR® options to best suit your needs: Yxoss CBR® Classic, Yxoss CBR® Protect, and now Yxoss CBR® Fully Protect! The new Yxoss CBR® Fully Protect has the same characteristics as the other configurations: 3D-printed custom-made titanium mesh that accurately reflects specific patient data, provides a solution for both vertical and horizontal ridge augmentation procedures, and gives the opportunity for integrated implant positioning.

In addition, Yxoss CBR® Fully Protect maintains the same established benefits of the Yxoss CBR® family: removes time-consuming, cutting, shaping, and adapting titanium mesh, gives the opportunity to reduce surgery time due to perfect fit without complex adaptations, and eliminates sharp edges and challenging removal which inhibits proper healing. The easy removal design allows for all Yxoss CBR® products to be removed easily with pre-defined breaking points.

For complex bone defects, needs will vary based on the position and extent of the defect, the patient’s anatomy, overall treatment requirements, and personal preference. The benefit of Yxoss CBR® Fully Protect is its fully microstructured surface that protects from tissue ingrowth. Having a dense microstructure across the complete scaffold allows for high stability and space maintenance, very easy removal, and enables good bone maturation due to a very well-vascularized tissue.

For more information about Yxoss CBR® Fully Protect and to stay updated on the latest news and offers from Geistlich, please visit https://geistlich.us/

Geistlich Pharma North America announced today the launch of Reoss’s latest innovation, Yxoss CBR® Fully Protect, the newest addition to the Yxoss CBR® Family!

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

References

Righesso, L A R et al. “Dynamic contrast-enhanced magnetic resonance imaging for monitoring neovascularization during bone regeneration-a randomized in vivo study in rabbits.” Clinical oral investigations vol. 25,10 (2021): 5843-5854. doi:10.1007/s00784-021-03889-6
Zaffe, Davide, and Ferdinando D’Avenia. “A novel bone scraper for intraoral harvesting: a device for filling small bone defects.” Clinical oral implants research vol. 18,4 (2007): 525-33. doi:10.1111/j.1600-0501.2007.01368

Geistlich Unveils Exciting Product Line Expansion: Introducing the SafeScraper TWIST VOLUMIZER

March 20, 2024

Geistlich Pharma North America announced today the launch of its latest innovation with META, the SafeScraper TWIST VOLUMIZER, the newest addition to the SafeScraper Family!

The new SafeScraper Twist VOLUMIZER provides the established benefits of the proven SAFESCRAPER TWIST curve: it provides an easy method for harvesting autogenous cortical bone for use in grafted sites with a minimally invasive technique.

Due to the exceptional functionality of the instrument, the ergonomic design provides excellent control during the harvesting procedure. The curved tip of the instrument facilitates easy access to donor sites, which makes it ideal for both minor and major harvesting procedures.

The SafeScraper Twist VOLUMIZER is the extra volume version of the SafeScraper Twist; it offers the same performance of rapid and accurate collection of autologous cortical bone, while collecting a larger bone volume.

This product has a redesigned blade with double grooves that allow for three collecting surfaces. The cutting performance reduces patient discomfort, and the quality of harvested bone for use in grafted sites promotes graft acceptance, neovascularization, and bone regeneration. ^1,2

For more information about the SafeScraper TWIST VOLUMIZER and to stay updated on the latest news and offers from Geistlich, please visit https://geistlich.us/

Geistlich Pharma North America announced today the launch of its latest innovation with META, the SafeScraper TWIST VOLUMIZER, the newest addition to the SafeScraper Family!

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

References

Righesso, L A R et al. “Dynamic contrast-enhanced magnetic resonance imaging for monitoring neovascularization during bone regeneration-a randomized in vivo study in rabbits.” Clinical oral investigations vol. 25,10 (2021): 5843-5854. doi:10.1007/s00784-021-03889-6
Zaffe, Davide, and Ferdinando D’Avenia. “A novel bone scraper for intraoral harvesting: a device for filling small bone defects.” Clinical oral implants research vol. 18,4 (2007): 525-33. doi:10.1111/j.1600-0501.2007.01368

Celebrating Innovation and Legacy: Geistlich Pharma’s 11th Annual Philip J. Boyne Scholarship Award

December 07, 2023

Geistlich Pharma North America, Inc. proudly announces the successful conclusion of the 11th annual Philip J. Boyne Scholarship Award. This prestigious scholarship, born out of the shared enthusiasm for innovation and bone regeneration between Dr. Philip J. Boyne and Dr. Peter Geistlich, continues to make a lasting impact on the field. The scholarship, established to honor the memory and collaborative spirit of these two pioneers, recognizes and supports residents who embody their commitment to advancing oral and maxillofacial surgery.

Honoring a Legacy:

The friendship between Dr. Philip J. Boyne and Dr. Peter Geistlich laid the foundation for groundbreaking developments in the field, culminating in the creation of Geistlich Bio-Oss®. To pay tribute to their enduring legacy, Geistlich Pharma North America, Inc. established the Philip J. Boyne Scholarship, an initiative that serves as a beacon for aspiring professionals who share the same spirit of innovation.

A Decade of Support and Empowerment:

Since its inception in 2011, the Philip J. Boyne Scholarship has empowered hundreds of residents from Oral and Maxillofacial Surgery (OMS) Programs across the country. These aspiring professionals have been given the invaluable opportunity to participate in the AAOMS Dental Implant Conference held annually in Chicago. This exposure to cutting-edge research, techniques, and networking has played a role in shaping the future of oral and maxillofacial surgery.

Commitment to Excellence:

This year, the commitment to excellence and the advancement of the field reached new heights, with scholarships awarded to 40 residents. Geistlich Pharma North America, Inc. continues to demonstrate its dedication to fostering the next generation of leaders and innovators.

Recognition and Celebration:

The culmination of this year’s scholarship program was celebrated at the annual cocktail reception on November 30, 2023, at the Sheraton Grand Hotel, Chicago, coinciding with the AAOMS Dental Implant Conference. This event provided a platform to recognize the outstanding achievements of the scholarship recipients, creating an atmosphere of camaraderie and collaboration among professionals in the field.

Geistlich Pharma North America, Inc. remains at the forefront of advancing oral and maxillofacial surgery through its commitment to innovation and education. The Philip J. Boyne Scholarship stands as a testament to the company’s dedication to nurturing the talents and aspirations of the next generation, ensuring a legacy of excellence in the ever-evolving field of oral and maxillofacial surgery.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.

Diego Gabathuler becomes the new CEO of Geistlich

December 01, 2023

Geistlich Pharma AG has appointed Diego Gabathuler as its new CEO, effective December 1, 2023. He succeeds Ralf Halbach, who departed the company in August 2023.

Diego Gabathuler is a 49-year-old Swiss National who brings a broad range of experience from various management positions as well as extensive knowledge in business development and strategic marketing.

Most recently, he was CEO of the dental company Ivoclar. He has expertise in the MedTech sector, excellent leadership qualities, and a proven strategic acumen. His professional career also includes management positions at international digital-tech companies such as Logitech, Activision, and Electronic Arts.

Andreas Geistlich, Chairman of the Board of Directors, who held the CEO position on an interim basis: “The Geistlich strategic plan includes further investment in new products, solutions, and technologies in order to apply regenerative medicine in helping even more people around the world. We are convinced that Diego Gabathuler’s expertise will support us significantly in this mission.”

Geistlich wishes Diego a successful start, and we look forward to working with him to further advance the future of regenerative medicine.

Geistlich appoints Diego Gabathuler as new CEO. As a proven leader, he brings many years of experience in the MedTech industry and will continue to drive the company’s expansion strategy in regenerative medicine.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.

Geistlich Pharma AG Executive Chairman, Dr. Andreas Geistlich, Honored with AAOMS Special Citation Award

For Immediate Release:

PRINCETON, N.J. October 2, 2023 – Geistlich Pharma North America Inc. is pleased to announce that our Executive Chairman, Dr. Andreas Geistlich, has been awarded the prestigious American Association of Oral and Maxillofacial Surgeons (AAOMS) Board of Trustees Special Citation Award for the company’s exceptional and longstanding contributions to the field of Oral and Maxillofacial Surgery.

“Dr. Geistlich, the Geistlich Family and Geistlich Pharma AG are all prominent supporters of AAOMS and our larger specialty. In 2013, Dr. Peter Geistlich founded the Osteo Science Foundation with the mission of further innovating the use of regenerative medicine within oral and maxillofacial surgery and improving patient care. Now celebrating its 10th anniversary, Osteo Science has contributed over $3 million toward oral and maxillofacial research,” said American Association of Oral and Maxillofacial Surgeons. “For Dr. Geistlich’s ongoing support to the betterment of the specialty, we present him with the Board of Trustees Special Citation Award.”

“It is a great honor for us to celebrate Osteo Science Foundation’s 10th Anniversary at the 105th AAOMS Annual Meeting. We are especially proud to have Dr. Andreas Geistlich recognized by AAOMS with a Special Citation during the Opening Ceremony this year. Osteo Science Foundation succeeds because of the valuable partnership with Dr. Geistlich and his family, with Geistlich Pharma, and with the leadership and membership of AAOMS,” stated Paul Tiwana, DDS, MD, FACS, FACD, Chair, Osteo Science Foundation.

The Special Citation Award was presented to Dr. Andreas Geistlich, at the 105th Annual AAOMS Meeting Opening Awards Ceremony on September 20, 2023, in San Diego, CA. The event brought together leaders, professionals, and enthusiasts from the Oral and Maxillofacial community to celebrate his remarkable achievements and contributions.

The AAOMS Board of Trustees Special Citation Award is a testament to the dedication, impact, and unwavering commitment of Geistlich to the OMS community. Geistlich extends its heartfelt congratulations to Dr. Geistlich on receiving this award.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

https://www.lynchbiologics.com/

iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.

Geistlich announces the dramatic expansion of their allograft portfolio – vallos^® sets the pace for regeneration

PRINCETON, N.J., March 16, 2023 /PRNewswire/ – Geistlich Pharma North America Inc. is pleased to introduce a growing variety of vallos^® allograft configurations to increase treatment flexibility through its partnership with a world-leading allograft provider.

This expanded Geistlich Select product line brings an added confidence to regenerative procedures with:

A full portfolio of 35 variations includes granules, fibers, demineralized, mineralized, and blended allografts
A single source supplier that ensures consistent product quality¹
Cortico-cancellous bone which is known to provide a natural scaffold for cell attachment and infiltration²
Stringent donor selection and proprietary aseptic processing that protects the native integrity of the graft

With multiple sizes and configurations available, the vallos^® allograft line allows clinicians to choose exactly what they need for each procedure. For smaller routine defects, vallos^® granules are ideal, while vallos^®f fibers are designed for larger, more complex defects.

“We are thrilled to introduce our new partner MTF Biologics – together we share a passion for regeneration, scientific advancement, and a commitment to quality. Our combined values and dedication to patient care makes this an outstanding collaboration. We look forward to a long and successful partnership.”
Les Burrows, General Manager of Geistlich Pharma North America.

vallos™

Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Our expanded vallos^® and vallos^®f portfolio bring clinicians even more options to enhance their ability to manage a variety of clinical indications and we are proud that Geistlich is now the company of choice for all their bone substitute needs.

About MTF Biologics^® – MTF Biologics® is a physician-led non-profit organization with 35 years of experience, dedicated to providing clinically sound and safe allograft tissue. The company has the largest recovery network and the most stringent donor screening in the industry, with less than 2% of all donated tissue accepted.¹MTF Biologics^® is the only tissue bank that utilizes The Vanguard Method^™ for quantitative and qualitative tissue testing and analysis – exceeding industry standards. All tissues are 100% aseptically processed, which avoids the use of harsh chemicals that can compromise the integrity of the tissue. MTF Biologics^® advances the science of tissue transplantation by awarding grants that fund groundbreaking research and is proud to support researchers and clinicians throughout their careers.

About Geistlich Pharma North America Inc. – With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products. This begins with our world-class bone substitute Geistlich Bio-Oss^® and Geistlich vallomix™ the first allograft/xenograft bone substitute. Resorbable collagen membrane Geistlich Bio-Gide^® extends its reach with Geistlich Bio-Gide^® Compressed for an alternative handling experience. Our collagen matrix Geistlich Mucograft^® is ideal for soft-tissue regeneration, and our volume-stable collagen matrix breakthrough Geistlich Fibro-Gide^® providing an alternative to connective tissue grafts. Finally, our GEM 21S^®, growth-factor enhanced matrix, is engineered to stimulate wound healing and bone regeneration. Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
902 Carnegie Center, Suite 360
Princeton, NJ 08540 USA

Home Page:
https://geistlich.us
LinkedIn
Instagram
Facebook

Contact:
Ron Frezel: [email protected]

Data on file, MTF Biologics^®
Roberts TT and Rosenbaum AI. Bone grafts, bone substitutes and orthobiologics; The bridge between basic science and clinical advancements in fracture healing. 2012.Organogenesis 8 (114-124)

Geistlich unveils vallos™ – a new demineralized allograft that sets the pace for regeneration

For Immediate Release:

Princeton, New Jersey November 7, 2022: Geistlich Pharma North America Inc. is setting the pace for expanded treatment options with the introduction of vallos™, our first demineralized allograft.

With two formulations for treatment flexibility, vallos™ granules are ideally suited for smaller routine defects while vallos™f fibers are designed for larger more complex defects. This Geistlich Select product line brings an added confidence to regenerative procedures, with:

Verified osteoinductive potential in every lot¹
Consistent product quality¹
Proven regenerative capacity by exhibiting all five elements of bone formation¹
Vital bone after 18-20 weeks²

“We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family.”
Les Burrows, General Manager of Geistlich Pharma North America.

vallos™

Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Demineralized vallos™ and vallos™f offer clinicians more options to enhance their ability to manage a variety of clinical indications and are the first products to become part of the Geistlich Select family.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products. This begins with our world-class bone substitute Geistlich Bio-Oss® and its full line of sizes and formulations. Resorbable collagen membrane Geistlich Bio-Gide® extends its reach with two new products: Geistlich Bio-Gide® Compressed for an alternative handling experience; and uniquely pre-cut Geistlich Bio-Gide® Shape designed for the treatment of non-intact extraction sockets. Finally, our collagen matrix Geistlich Mucograft® is ideal for soft-tissue regeneration, and our volume-stable collagen matrix breakthrough Geistlich Fibro-Gide® providing an alternative to connective tissue grafts.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Exactly Like No Other. To learn more about Geistlich, please visit us on our website https://dental.geistlich-na.com, or connect and follow us on LinkedIn, Instagram and Facebook.

Media Contact:

For more information on vallos™ and vallos™f, please visit: https://vallos.geistlich-na.com Or contact Ron Frezel at: [email protected]

Geistlich Pharma North America Inc.
902 Carnegie Center, Suite 360
Princeton, NJ 08540 USA

Home Page:
https://dental.geistlich-na.com
https://www.lynchbiologics.com/
LinkedIn
Instagram
Facebook

Contact:
Ron Frezel: [email protected]

Data on file, DCI Donor Services Tissue Bank
Robert A Wood & Brian L Mealey: J Periodontol. 2012 Mar;83(3):329-36. (Clinical Study)

Geistlich Pharma North America, Inc. acquires Lynch Biologics, LLC, a biologics and tissue engineering company

For Immediate Release:

Princeton, New Jersey October 26, 2022: Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer, and sole provider of GEM 21S^®, the first recombinant growth factor product for use in oral regenerative surgery. This acquisition further strengthens the regenerative product portfolio of Geistlich and provides significant growth potential.

“I am so excited to combine Lynch Biologics with Geistlich Pharma North America. We look forward to being a part of the Geistlich Pharma North America team, known for their tremendous professionalism, integrity, and commitment to improving care for patients,” stated Sam Lynch, DMD, DMSC, CEO, Lynch Biologics. “I believe this is an exciting opportunity as we bring together the companies with the widely used biologic and the world market leader in dental biomaterials, which is an ideal combination to serve our customers in the oral regenerative space. Equally, I am thrilled to expand our training and education capabilities, as well as continue our clinical research. Having played a small role in helping to launch Geistlich products in the US many years ago and now having the ability years later to work with this team to bring new cutting-edge technologies together is incredibly fulfilling for me personally.”

“We are delighted to welcome Lynch Biologics to our Geistlich family and to have the opportunity to work with Dr. Lynch and his talented team that are so passionate and committed to developing products that make a difference in the field of regeneration. I couldn’t be more excited about our future together,” said Les Burrows, General Manager, Geistlich Pharma North America. “GEM 21S augments our expanding portfolio of regenerative solutions. This acquisition allows us to align with another organization that has the same beliefs, clinically proven products, and a commitment to ongoing research. This sets the stage for additional new products that support our mission to drive regeneration in oral surgery.”

“The acquisition of Lynch Biologics demonstrates our commitment to the clinicians and patients of the United States and further enhances our portfolio of innovative products used worldwide, said Dr. Ralf P. Halbach, Chief Executive Officer, Geistlich Pharma AG. “We have long admired the pioneering spirit of Dr. Sam Lynch and welcome Lynch Biologics into our family.”

Following the close of this acquisition, as a member of the Geistlich team Dr. Lynch will continue to support Lynch Biologic customers through best-in-class dental education and trainings, as well as assist in addressing any questions doctors may have regarding GEM 21S®. In addition, we’re seamlessly integrating our operations, so all of Lynch Biologic customers can continue to order GEM 21S® online, call the same 1-800 number, and most importantly, continue to get the same personalized service.

The combination of two regenerative leaders offers:

Expanded regenerative solutions for clinicians and their patients
A combined team of purpose-driven leaders and highly skilled experts
Strengthened product development, clinical research, and education on new regenerative technologies
A shared commitment to research, quality, and safety

About Lynch Biologics

Lynch Biologics is a regenerative medicine and tissue engineering company supplying advanced biotechnology products that promote healing and tissue regeneration spearheaded by GEM 21S®, and other widely used regenerative products, for periodontal and oral and maxillofacial indications. Their products have been used to help millions of patients regenerate lost bone and soft tissues and continue to be among the most popular grafting products with our dental colleagues.

GEM 21S® Growth-factor Enhanced Matrix was developed utilizing innovative tissue engineering principles which combine a bioactive protein (highly purified recombinant human platelet-derived growth factor, rhPDGF-BB) with an osteoconductive matrix (beta tricalcium phosphate, β-TCP).

This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.

About Geistlich North America Inc.

Geistlich Pharma North America brings the leader in regenerative dentistry directly to the United States and Canada. For 171 years, our respected family-owned Swiss parent company, Geistlich Pharma AG, has pioneered technological advances that make regenerative treatment with safe and naturally sourced biomaterials the preferred choice for clinical predictability.

Geistlich is the world market leader in regenerative dentistry^1,2. All our products are investigated rigorously before being released on the market. Geistlich products have been tested and developed for use in various therapeutic areas in collaboration with more than 100 universities and leading surgeons.

We consistently meet or exceed industry safety and quality standards and follow a continuous training program for our employees. Meeting international scientific standards is a core principle of Geistlich Biomaterials. Geistlich Bio-Oss® and Geistlich Bio-Gide® bone regeneration materials are the most researched products in regenerative dentistry worldwide^1,2.

Moreover, we are committed to guiding clinicians through regenerative education, whether through physical courses, webinars, or through our BIOBRIEF clinical case series.

These substantial efforts lead to a single goal – to provide the highest standard of product quality and safety in order to improve the patient’s quality of life.

Geistlich Pharma North America Inc.

400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

https://geislich.us